Cat. No. 3270
Chemical Name: 4,5-Dihydro-3-phenyl-5-isoxazoleace
Biological ActivityOrally active immunomodulatory agent that primarily targets macrophages. Inhibits TNF-α secretion via interference of macrophage toll-like receptor (TLR) 4 and TLR 2/6 signaling pathway. Also reduces the secretion of pro-inflammatory cytokines IL1-β, IL-10 and IFN-γ. Antidiabetogenic; prevents IL-β and IFN-γ-induced pancreatic islet cell death in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Stojanovic et al (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin.Immunol. 123 311. PMID: 17449326.
Stosic-Grujicic et al (2007) A potent immunomodulatory compound (S,R)-3-phenyl-4,5-dihydro-5-isoxasoleacetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J.Pharmacol.Exp.Ther. 320 1038. PMID: 17148780.
Mangano et al (2008) In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur.J.Pharmacol. 586 313. PMID: 18374912.
If you know of a relevant citation for this product please let us know.
Keywords: GIT 27, supplier, Interfers, TLR4, TLR2/6, signalling, Immunomodulators, reduces, production, pro-inflammatory, cytokines, Toll-like, Receptors, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, GIT27
Find multiple products by catalog number
New Products in this Area
Potent NLRP3 inflammasome inhibitor; inhibits IL-1β productionBengamide B
Potent inhibitor of NF-κB activation
July 7 - 11, 2015
Rio de Janeiro, Brazil